KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Inventory (2020 - 2025)

Historic Inventory for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $108.5 million.

  • Esperion Therapeutics' Inventory rose 3550.1% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.5 million, marking a year-over-year increase of 3550.1%. This contributed to the annual value of $94.5 million for FY2024, which is 4399.07% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Inventory is $108.5 million, which was up 3550.1% from $114.5 million recorded in Q2 2025.
  • Esperion Therapeutics' Inventory's 5-year high stood at $114.5 million during Q2 2025, with a 5-year trough of $20.0 million in Q1 2021.
  • For the 5-year period, Esperion Therapeutics' Inventory averaged around $57.8 million, with its median value being $45.7 million (2023).
  • Per our database at Business Quant, Esperion Therapeutics' Inventory skyrocketed by 98799.57% in 2021 and then tumbled by 1303.13% in 2022.
  • Esperion Therapeutics' Inventory (Quarter) stood at $34.4 million in 2021, then rose by 2.35% to $35.2 million in 2022, then surged by 86.42% to $65.6 million in 2023, then soared by 43.99% to $94.5 million in 2024, then rose by 14.87% to $108.5 million in 2025.
  • Its last three reported values are $108.5 million in Q3 2025, $114.5 million for Q2 2025, and $99.3 million during Q1 2025.